Background and Aims There are guidelines for the medical management of cirrhosis and associated quality indicators (QIs), but QIs focusing on standards for palliative aspects of care are needed. Methods We convened a 9-member, multidisciplinary expert panel and used RAND/UCLA modified Delphi methods to develop palliative care quality indicators for patients with cirrhosis. Experts were provided with a report based on a systematic review of the literature that contained evidence concerning the proposed candidate QIs. Panelists rated QIs prior to a planned meeting using a standard 9-point RAND appropriateness scale. These ratings guided discussion during a day-long phone conference meeting, and final ratings were then provided by panel members. Final QI scores were computed and QIs with a final median score of greater than or equal to 7, and no disagreement was included in the final set. Results Among 28 candidate QIs, the panel rated 19 as valid measures of quality care. These 19 quality indicators cover care related to information and care planning (13) and supportive care (6). Conclusions These QIs are evidence-based process measures of care that may be useful to improve the quality of palliative care. Research is needed to better understand the quality of palliative care provided to patients with cirrhosis.
Introduction
Several studies have shown evidence of the poor quality of end-of-life care in the USA [1, 2] . Understanding and meeting palliative care needs of patients with serious illness has become increasingly recognized as an important part of high-value care [3] . A recent study by Wachterman et al. showed that end-of-life care for patients with cancer as rated by families in after-death surveys was higher than for patients who died of non-cancer organ failure. Patients with cancer were more likely to have a palliative care consult or a decision about code status compared to patients with other serious illnesses [4] .
Similarly, while there are several quality measures developed for palliative or supportive care in cancer [5] , there is a dearth of commonly used guidelines or process of care quality measures specifically designed for measuring the quality of palliative care for patients with cirrhosis. Despite this lack of guidelines, patients with cirrhosis have significant communication challenges and symptom burden suggesting similar palliative care needs as in the cancer population.
End-stage liver disease (ESLD), the twelfth leading cause of death in the USA [6] , is known to be a lifelimiting illness whose only cure is transplant. Transplant, when possible, can have 1-year survival of greater than 80 %, but patients who do not undergo transplant will die from their disease and little is known about the outcomes of those patients with difficult post-transplant courses [7] , highlighting the need for nuanced advance care planning specific to the population [8] . In fact, we learned from the SUPPORT study that discrepancies between reported desired care and care received among patients with cirrhosis at end of life were likely, in part, due to communication challenges related to the possibility of transplant [9] .
Prior to death, patients with liver disease often suffer from poor health-related quality of life [10] and their burden of pain is similar as that for patients with lung and colon cancer [9] . Further supporting the need for cirrhosisspecific palliative care measures, there are treatment challenges unique to this disease since liver dysfunction often leads to variation in metabolism of commonly used supportive medications [8] .
There are guidelines for the medical management of cirrhosis and an accompanying comprehensive set of quality indicators (QIs) [11] ; however, this set does not include advance care planning and some aspects of symptom management. We aimed to supplement that set of quality indicators with QIs that focus on palliative care for this population.
Methods
We used the RAND/University of California, Los Angeles (UCLA) appropriateness method to supplement a previously developed set of cirrhosis QIs with QIs specifically designed to measure the quality of palliative care among patients with ESLD [11] . This method for developing QIs includes three distinct steps ([1] development of candidate indicators [2] systematic review of the literature and [3] expert panel review) and has been shown to be a reliable and valid method for development of process of care quality measures that are linked to important patient outcomes [12] [13] [14] [15] [16] .
Development of Quality Indicators
In prior work, quality of care measured using process of care measures has been linked with improved survival and quality of life consistent with the Donabedian Quality of Care Framework [14, 15, 17] . Conceptually, palliative care QIs focused on symptom management and communication link to improved outcomes of quality of death, health-related quality of life, and patient and family experience of care (Fig. 1) .
We developed candidate QIs after reviewing palliative care guidelines, review articles related to palliative care and cirrhosis [8, [18] [19] [20] [21] [22] [23] [24] [25] [26] , palliative care QIs that have been developed for other populations [27, 28] , and conducting a systematic literature review. While palliative care can cover many domains, we restricted indicators to those that were primarily about clinical decision making and these were categorized into Information and Care Planning and Supportive Care domains. We excluded indicators specifically related to palliative treatments for hepatocellular cancer (HCC) such as the use of sorafenib, transcatheter arterial chemoembolization (TACE), and radiofrequency ablation (RFA) since it was beyond the scope of this effort.
Each QI contains an ''IF'' statement that defines the eligible population to which the indicator applies, a ''THEN'' statement indicating the recommended care process to be measured, and a ''BECAUSE'' statement that summarizes the primary indication for the care process.
Review of Literature
We searched the literature to capture all relevant data for interventions aimed at addressing common symptoms and problems at the end of life for patients with ESLD. Articles were identified through MEDLINE, the Cochrane Database of Systematic Reviews, Cochrane Database of Abstracts of Reviews of Effects and the Cochrane Register of Clinical Trials (1990 through 12/14/2012, details in appendix). Two reviewers (AW and SA) conducted dual review using review criteria of 1888 titles in groups of 100 and resolved conflicts. For the third set of 100 titles, we achieved 96 % agreement (Kappa 0.78) suggesting excellent agreement and thus conducted single review for the remainder of the titles. The same dual-review process for abstract review yielded 82 articles that were reviewed for evidence related to relevant quality indicators.
To enrich the review, we later performed supplemental searches and included high-impact articles addressing palliative care that included patients other than those with ESLD since there are few studies in this area. The importance of the expert panel for determination of these measures is highlighted by the fact that many of the QIs proposed here are supported by expert clinical approach and foundational ethical principles rather than empiric evidence.
We also evaluated guidelines published after 1997 using the National Guidelines Clearinghouse and all data available related to liver disease from CareSearch, a palliative care knowledge network.
For each QI, we rated the evidence as Level 1 (randomized control trials), Level II (non-randomized controlled trials, cohort or case analysis, or multiple time series), or Level III (textbooks, opinions, and descriptive studies). All of the proposed QIs had level III evidence using these standards. All indicators were conservatively rated Level III given limited data specific to advanced endstage liver disease. However, the expert panel did review evidence from the cancer literature that provided Level I for palliative care indicators (QI #1,2,5) and Level II evidence for advance care planning indicators (QI #6,7,8,9,10,13,14A,15) within the information and care planning domain [29] [30] [31] [32] .
Expert Panel
The multidisciplinary expert panel included various clinical specialties (one hospitalist, one palliative care physician, one primary care physician, and 5 gastroenterologists) and experts from varied geographic locations (Missouri, Maryland, Virginia, Texas, California, Connecticut, and Washington, DC). The hospitalist, palliative care physician, and primary care physician all had extensive health services research experience and had been involved in the past with the development of QIs using this same methodology. The gastroenterologists represented varied interests and skills including transplant hepatology, health services research, and public health.
We used the RAND/UCLA process to rate the appropriateness of each QI that was proposed by the research team. The process included two rounds of rating the validity of the indicators, one prior to the interactive telephone conference and one at the conclusion of this conference. The rating system involved a 1-9 scale where 1 represented the least valid indicator and 9 represented the most valid. Panel members were provided written instruction regarding the process for the first round of rating and both written and verbal instructions for the final rating that included the standard definitions for appropriate and inappropriate from RAND/UCLA methodology [16] .
Prior to the first round of rating, panel members reviewed a report based on the systematic literature review. This report included data relevant to the proposed QIs as well as a set of definitions for terms used in the QIs. For purposes of the initial round of rating, ESLD was defined as a patient with CTP Class C or MELD score greater than or equal to 20. Initial ratings of the panel were de-identified and distributed to all panel members to guide discussion during the interactive conference.
The expert panel conference took place via a conference phone and interactive-web meeting over a period of seven hours during which panelists discussed each proposed definition and quality indicator in detail in preparation for final ratings. QIs with a final median score of greater than or equal to 7 were included in the final set. We decided a priori that if there was disagreement, meaning at least 3 panelists rated in lowest tertile [1, 2] despite having a median score in the highest tertial (7-8-9), the indicator would not be included in the final set [16] . None of the indicators, however, were excluded based on disagreement. All nine panel members participated in both rounds of ratings.
Results
During the panel conference, the first point of discussion was the definition of ESLD. After substantial discussion, panel members decided to make a slight alteration to the definition of ESLD and limited the denominator for these QIs to patients with advanced ESLD who have either a MELD score of greater than or equal to 20 or a CTP score of 12 (rather than that of 10 used for pre-panel ratings). All other definitions were left unchanged after discussion ( During panel discussion, slight modifications were made to candidate QIs resulting in 3 additional QIs (details of modifications are in footnote of Table 2 ). There were 28 initial candidate QIs and 31 total QIs were reviewed during the second and final rounds. The panel rated 19 as valid measures of quality care (Table 2 ) and 12 were rejected from inclusion in the final set ( Table 3 ). The 19 included quality indicators cover the domains of information and care planning (13 indicators) and supportive care (6 indicators).
Discussion
High-quality care should promote quality of life as well as longevity, and yet, patients and families often are placed in the position of having to make trade-offs between these goals. It is crucial that clinicians help patients with advanced illness navigate these choices. While there are general guidelines for offering palliative care for ''persons with debilitating and life-threatening illness'' [18] , how to apply such general guidelines to patients with cirrhosis is challenging at best. In order to fill this gap and supplement an already developed comprehensive set of QIs for cirrhosis, we developed 19 QIs focused on the provision of high-quality palliative care for patients with advanced cirrhosis.
These QIs were developed based on previously fielded palliative care QIs for vulnerable elders and patients with cancer [27, 28] and evidence-based approaches to care for patients with serious illness [29] [30] [31] [32] [33] [34] . Notably, good communication about end-of-life care and early elicitation of preferences have been associated with better quality-of-life outcomes for patients and caregivers. Most of the identified care processes do not require specialty palliative care teams; primary care and specialist clinicians can integrate these practices into care of seriously ill patients.
There are several limitations to this quality indicator set. It is important to note that palliative care can be provided throughout the trajectory of illness, and these indicators simply serve as a marker of what a minimally acceptable bar of care should be. They provide a tool to measure the quality of palliative care provided to patients with advanced end-stage liver disease using a comprehensive set of measures. However, any quality indicator set is necessarily limited in scope for several reasons and this is also the case for these quality indicators. We do not cover topics that have limited evidence for explicit indicators among patients with serious illness (for example, spiritual care or dealing with comorbid substance abuse), and in other instances, proposed indicators on specific topics (such as caregiver support) were not included after review by expert panel. Furthermore, the expert panel did not have non-MD clinician representation, such as social work and nursing, and this should be considered for future work in this area.
High-quality end-of-life care from the perspective of the patient requires open, patient-centered communication, effective pain and symptom management, and the facilitation of the patient's ability to prepare for death [35] . These indicators provide a practical first step to measuring how well these goals for patients with cirrhosis are being met. The comprehensive nature of the UCLA/RAND methodology used here supports the content validity of these measures. Future research should investigate the feasibility and reliability of these measures and their link to important outcomes such as patient and caregiver satisfaction with care. Advance care planning Documentation of a surrogate and/or patient preferences in the medical record or in an advance directive, and/or in a Physician Orders for Life-Sustaining Treatment (POLST) form
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